Charles Harris

Charles Harris

Auto-generated profile, based on publicly available information

Charles Harris

Eli Lilly and Company Indianapolis Indiana USA

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 February 2025 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Open access
MLMichelle Look
Michelle Look
JDJulia P. Dunn
Julia P. Dunn
RKRobert F Kushner
Robert F Kushner
DCDachuang Cao
Dachuang Cao
CHCharles Harris
Charles Harris
RGRyan Griffin
Ryan Griffin
Aims: We assessed changes in body composition following tirzepatide treatment in a substudy of participants with obesity or overweight from the SURMOUNT‐1 trial, overall and post hoc in clinically relevant subgroups. Materials and Methods: Substudy participants ( n = 160 of the 2539 in SURMOUNT‐1) underwent dual‐energy X‐ray absorptiometry (DXA) at baseline and Week 72. Body composition parameters were evaluated by analysis of covariance, logistic regression or Fisher's exact test. Post hoc subgroup analyses were conducted by sex (female or male), age (<50, 50 to 15.3 to ≤25.9 kg, or >25.9 kg). Results: The 160 participants (pooled tirzepatide doses n = 124, placebo n = 36) with baseline and end of study DXA data were 73% female and had a mean weight of 102.5 kg and body mass index of 38.0 kg/m 2 . The change in body weight, fat mass and lean mass from baseline to Week 72 was −21.3%, −33.9% and −10.9% with tirzepatide and −5.3%, −8.2% and −2.6% with placebo, respectively ( p < 0.001 for all comparisons). Of the body weight lost, approximately 75% was fat mass and 25% was lean mass for both tirzepatide and placebo. These proportions remained consistent across most subgroup analyses. Conclusions: In participants with obesity or overweight from the SURMOUNT‐1 trial, tirzepatide treatment significantly reduced body weight, fat mass and lean mass compared with placebo, while in post hoc analyses, the proportion of body weight lost as fat or lean mass was relatively consistent including in clinically relevant subgroups.